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Abstract: In this study, we utilized an integrated bioinformatics and computational biology approach in search of new 
BH3-only proteins belonging to the BCL2 family of apoptotic regulators. The BH3 (BCL2 homology 3) domain mediates 
specific binding interactions among various BCL2 family members. It is composed of an amphipathic α-helical region of 
approximately 13 residues that has only a few amino acids that are highly conserved across all members. Using a 
generalized motif, we performed a genome-wide search for novel BH3-containing proteins in the NCBI Consensus 
Coding Sequence (CCDS) database. In addition to known pro-apoptotic BH3-only proteins, 197 proteins were recovered 
that satisfied the search criteria. These were categorized according to α-helical content and predictive binding to BCL-xL 
(encoded by BCL2L1) and MCL-1, two representative anti-apoptotic BCL2 family members, using position-specific 
scoring matrix models. Notably, the list is enriched for proteins associated with autophagy as well as a broad spectrum of 
cellular stress responses such as endoplasmic reticulum stress, oxidative stress, antiviral defense, and the DNA damage 
response. Several potential novel BH3-containing proteins are highlighted. In particular, the analysis strongly suggests 
that the apoptosis inhibitor and DNA damage response regulator, AVEN, which was originally isolated as a BCL-xL-
interacting protein, is a functional BH3-only protein representing a distinct subclass of BCL2 family members. 
Keywords: Apoptosis, autophagy, DNA damage checkpoint. 
INTRODUCTION 
 Members of the B-cell lymphoma-2 (BCL2) family of 
proteins are characterized by conserved regions known as 
BCL2 homology (BH) domains (designated BH1, BH2, BH3 
and BH4). Multiple BH domain-containing proteins include 
the anti-apoptotic proteins BCL2, BCL-xL, BCL-w, MCL-1 
and A1/BFL-1 and the pro-apoptotic proteins BAX, BAK, 
BCL2L14/BCL-G and BOK. By comparison, a subclass of 
pro-apoptotic BCL2 family members, referred to as BH3-
only proteins, possess only the BH3 domain. Members of 
this subclass include BAD, BBC3/PUMA, BCL2L11/BIM, 
BCL2L15/BFK, BMF, BID, BIK, HRK and PMAIP1/ 
NOXA [1, 2]. Structural studies have shown that the BH3 
domain of BH3-only proteins binds as an amphipathic α-
helix in a hydrophobic groove of anti-apoptotic BCL2 family 
members [3] and there is some evidence to suggest that the 
affinity of a BH3 domain peptide for anti-apoptotic BCL2 
proteins is influenced by the tendency of the peptide adopt 
the α-helical conformation required for binding [4, 5].  
 Day and coworkers have described a generalized motif 
composed of 13 residues that covers approximately two 
heptads of the α-helix of BH3 domains, Φ1ΣXXΦ2XXΦ3Σ’ 
DZΦ4Γ, where Φ1-Φ4 are hydrophobic residues, Σ and Σ’ are 
small residues, X is any amino acid, D is a conserved aspar- 
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tic acid, Z is usually an acidic residue and Γ is a hydrophilic 
residue capable of forming an intermolecular helix cap [6]. 
In all bona fide BH3-only proteins, the Φ2 hydrophobic 
residue is a leucine (L) [7]. The conserved L and D residues 
form key interactions with the cognate anti-apoptotic protein. 
L is buried in the protein-protein interface and packs against 
conserved residues provided by the anti-apoptotic protein, 
while the solvent-exposed D forms an ionic interaction with 
a conserved arginine in the BH1 domain of the anti-apoptotic 
protein [8]. Other binding interactions arise from the Φ1, Φ3 
and Φ4 hydrophobic residues. All anti-apoptotic proteins use 
the equivalent hydrophobic groove interface to bind multiple 
BH3-only proteins but they have distinct BH3 binding 
profiles [9-11]. In this regard, introducing two or three muta-
tions into the BIM BH3 sequence can generate considerable 
selectivity for BCL-xL relative to MCL-1 or vice versa [12, 
13]. Recently, Dutta and colleagues combinatorially mutated 
all four hydrophobic residues (Φ1-Φ4), the conserved D, and 
a sixth position of the BIM BH3 domain (X at position 3b 
according to their numbering convention; see Fig. 1) and 
used yeast surface display to identify peptides selective for 
binding to BCL-xL or MCL-1 [11]. They complemented this 
approach by performing binding assays with BCL-xL or 
MCL-1 and peptide arrays spotted with BIM BH3 peptides 
in which 10 of the 13 residues (including the 6 randomized 
in the yeast surface display library) were individually 
mutated. Using the combined data, they developed position-
specific scoring matrix (PSSM) models for BH3 binding 
specificity for BCL-xL and MCL-1.  
 Our group has a long-standing interest in the molecular 
mechanisms underlying growth and survival of malignant 
cells [14-18]. Here we describe an approach that combines 
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genome-wide consensus BH3 motif searching, α-helical 
secondary structure prediction and predictive PSSM models 
of binding to BCL-xL and MCL-1 in an attempt to identify 
novel BH3-containing proteins involved in cancer patho-
biology and therapeutic response.  
MATERIALS AND METHODOLOGY 
Bioinformatics 
 A search for new BH3-containing BCL2 family members 
was conducted using the NCBI CCDS database (http://www. 
ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi) for pro-
teins containing 13-amino acid sequences that match a 
consensus BH3 motif, Φ1ΣXXΦ2XXΦ3Σ’DZΦ4Γ, based on 
that described by Day and colleagues [6] with the following 
modifications: Φ1 represents ACGILMFPWVYET (BNIP1/ 
BNIP3L has E; HRK has T) [13]; Φ2 is L; Φ3 represents 
ACGILMFPWVYETS (BECN1 has T; BNIP3L has S) [13]; 
Φ4 represents ACGILMFPWVYET [13]; Σ represents 
GASCV (BOK has C; BCL2L14/BNIP3L have V); Σ’ 
represents GASC; X is a random amino acid; D is a 
conserved aspartic acid; Z represents DEKQLSW (NOXA 
has K; BCL2L14/BCL2L15/BMF have Q; BBC3/BECN1 
have L; BID has S; BNIP3L has W); and Γ represents an 
amino acid which is capable of forming an intermolecular 
helix cap, NDSTCGHYEV [19] . 
 The helical content of the putative BH3 sequences was 
determined from secondary structure predictions of all of the 
human protein sequences in the NCBI CCDS database using 
PredictProtein (www.predictprotein.org) PROFphd neural 
network secondary structure prediction software [20].  
 PSSM models derived by Dutta and colleagues were used 
to predict binding to BCL2L1/BCL-xL and MCL-1 [11]. The 
PSSM models were built using peptide array data from point 
mutations made in the background of a peptide derived from 
the BH3 region of BCL2L11/BIM (involving 10 positions-
2d, 2e, 2g, 3a, 3b, 3d, 3e, 3f, 3g, 4a-mutated to any of 
ADEFGHIKLNPQRSTV). The binding affinity score pre-
sented for each putative BH3 sequence is the sum of the 
score contributions of all 10 positions predicted by the 
revised PSSM model that incorporated 170 single-site muta-
tions plus selected sequences based on combinatorial 
mutations identified by yeast surface display [11].  
Molecular Dynamics Simulations 
 Molecular dynamics simulations of interactions between 
putative BH3 sequences and anti-apoptotic BCL2 family 
members were carried out essentially as we have described 
previously [21] except that GROMACS (Groningen Machine 
for Chemical Simulations) was used as the modeling 
software (www.gromacs.org) [22]. The starting coordinates 
for the simulations of the binding of the 25-mer AVEN and 
dAven peptides to BCL-xL were based on the BAD/BCL-xL 
complex (PDB code: 1G5J) [4]. The backbone conformation 
for the two peptide ligands ESQRGTDFSVLLSSAGDSF 
SQFRFA (AVEN) and AQLRAGDFQQLAQFPSLGGGHF 
TFG (dAven) was obtained from amino acids 301-325 of 
BAD with all sidechains rebuilt using the SCAP sidechain 
prediction program [23]. The GROMACS96 53a6 force field 
and Simple Point Charge (SPC) water model were chosen 
for the simulations. Using the “Pdb2gmx” tool available in 
GROMACS, hydrogen atoms present in the file were 
removed and then rebuilt according to the description in the 
force field. Energy minimization was performed on the 
initial structure of the ligand and receptor complex to relax 
possible strain after adding the force field and water model 
by using steepest-descent integration. The system was 
equilibrated for a period of 0.5 ns. The complex was then 
placed in the center of a cubic water box and the solute 
molecules were solvated with SPC water molecules using the 
GROMACS utility program “Genbox”. The total number of 
atoms in the two simulations varied between 26,000 and 
27,000. The system was neutralized by adding Na+ or Cl- 
ions to a concentration of 0.15 M NaCl using the 
GROMACS utility program “Genion”. In some simulations, 
excess Na+ or Cl- ions were added. This step was followed 
by an energy minimization and a position relaxation simula-
tion, each for 0.5 ns. Afterwards, the system was equilibrated 
for a period of 1 ns in two stages. First, a 0.5 ns stage 
 
Fig. (1). Alignment of AVEN proteins of human (NP_065104.1), chimpanzee (XP_510277.3), dog (XP_535418.2), mouse (NP_083120.2), 
chicken (NP_001005791.1) and fruit fly (NP_572817.1). Conserved BH3-like motifs in the human, chimpanzee, dog, mouse and chicken 
proteins are highlighted in blue with conserved L and D residues in red. Numbering using the heptad convention of Dutta and colleagues 
[11] is shown at the top. Note that the Drosophila protein has diverged considerably from the other proteins and does not contain a putative 
BH3 motif, but some common residues have been retained within the boxed region (referred to as Region II by Zou and colleagues [34]). 
The 25-mer AVEN and dAven peptides used in the molecular dynamics simulations of putative BH3 interactions with BCL-xL (Fig. 3) are 
underlined. 
       BH3 Motif          
  ---2------3------4--- 
  abcdefgabcdefgabcdefg 
Human       118   WDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDSEA   167 
Chimpanzee  114   WDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDSEA   163 
Dog         134   WDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFVEEKEWDGEV   183 
Mouse       106   WDRYQDTEKEVNGESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDGET   155 
Chicken     112   WNRYEDAEKEGQTECGESQRGTDFSVLLSSAGDSFSQFRFAEEKDWDTEN   161 
Fruit fly    91   VEQLGLDGAPIDENARAQLRAGDFQQLAQFPSLGGGHFTFGSEREWANVA   140 
     Region II          
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simulation was performed under the NVT ensemble (cons-
tant number of atoms, volume and temperature), relaxing the 
system and coupling it to the heat bath. The second stage 
consisted of a further 0.5 ns simulation without any restraints 
using the NPT ensemble (constant number of atoms, pres-
sure and temperature). Production runs constituted 20 ns of 
simulations under NPT conditions. The LINCS algorithm 
[24] was used to constrain all bonds involving hydrogen 
atoms. Periodic boundary conditions were applied in all 
three directions. The simulation temperature and pressure 
were 300 K and 1 bar, respectively. Temperature was 
maintained by using the Berendsen algorithm [25] with a 
coupling constant of 0.1 ps during the equilibration and 
production stages. For pressure coupling, the Berendsen 
algorithm with a coupling constant of 1.0 ps was adopted to 
maintain the boundary pressure. Non-bonded interactions 
were evaluated using a spherical cutoff of 14 Å. A time step 
of 0.001 ps was used for the simulations. 
RESULTS AND DISCUSSION 
Bioinformatics Search for Novel BH3-Only Proteins 
 By using a relaxed consensus sequence corresponding to 
BH3-containing pro-apoptotic BCL2 family members (see 
Materials and Methodology), we conducted a search of the 
NCBI CCDS database. A total of 279 sequences were 
recovered representing 214 genes (17 known BH3-contain-
ing genes and 197 potential BH3-only protein candidates) 
that satisfied the search criteria. As expected, included in this 
list were all of the known pro-apoptotic BH3-only proteins 
(BAD, BBC3/PUMA, BCL2L11/BIM, BCL2L15/BFK, 
BMF, BID, BIK, HRK, and PMAIP1/NOXA). Also present 
in the list were the multidomain pro-apoptotic proteins BAK, 
BAX, BCL2L14/BCL-G and BOK. In addition, two BH3-
containing proteins involved in autophagy, BECN1 and 
BNIP3L/NIX, were identified as were the previously recog-
nized BH3-containing proteins HUWE1/MULE, an E3 
ligase that ubiquitinates MCL-1, and RAD9A, a multifunc-
tional protein involved in cell death and the DNA damage 
checkpoint (Supplemental Files 1 and 2). 
 A PSSM was used to predict binding to BCL2L1/BCL-
xL and MCL-1. The PSSM was derived by Dutta and col-
leagues from binding analyses using peptide arrays and yeast 
surface display in which the effects of single-site and combi-
natorial point mutations were assessed in the background of 
a peptide corresponding to the BH3 region of BCL2L11/ 
BIM [11]. A prediction could be made for 111 of the 197 
candidates, and these are listed in Supplemental File 2 (pages 
6-45) in the descending order of their binding affinity scores 
for BCL2L1/BCL-xL. For the remaining candidates (86 
genes), a prediction was not possible because at least one of 
the amino acids in the motif was not contained in the PSSM 
matrix (Supplemental File 2, pages 46-72). Below we 
highlight several of these proteins as potential new BH3-
containing BCL2 family members.  
Putative BH3-Containing BCL2 Family-Binding Proteins 
AVEN (Apoptosis, Caspase Activation Inhibitor)  
 AVEN (also known as PDCD12; programmed cell death 
12) is a novel apoptosis inhibitor which binds to both BCL-
xL and the caspase regulator, apoptotic peptidase-activating 
factor-1 (Apaf-1) [26]. AVEN has been proposed to inhibit 
apoptosis in part by stabilizing BCL-xL [27]. Apaf-1 is a 
pro-apoptotic protein that accelerates apoptosis downstream 
of mitochondria by multimerizing to form the apoptosome 
complex, which activates caspase proteases [28]. AVEN 
interferes with the ability of Apaf-1 to self-associate, sug-
gesting that AVEN also impairs Apaf-1-mediated activation 
of caspases [26].  
 AVEN was identified in a yeast two-hybrid screen with 
BCL-xL as bait; the gene is broadly expressed and is con-
served in other mammalian species. Indirect immunofluore-
scence analysis indicated a diffuse nuclear staining pattern 
and a reticular cytoplasmic staining pattern consistent with 
intracellular membrane localization [26]. We identified a 
 
Fig. (2). ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) sequence alignment of AVEN versus BIK. “*”, identical; “:”, conserved 
substitutions; “.”, semi-conserved substitutions. The putative BH3-like motif in AVEN and the BIK BH3 domain are highlighted. 
AVEN  MQAERGARGGRGRRPGRGRPGGDRHSERPGAAAAVARGGGGGGGGDGGGRRGRGRGRGFR 60 
BIK   ------------------------------------------------------------ 
                                                                   
AVEN  GARGGRGGGGAPRGSRREPGGWGAGASAPVEDDSDAETYGEENDEQGNYSKRKIVSNWDR 120 
BIK   -----------------------MSEVRPLSRDILMETLLYEQLLEP--PTMEVLGMTDS 35 
                              .   *:. *   **   *:  :   .. :::.  *  
AVEN  YQDIEKEVNNESGESQRGTD-FSVLLSSAGDSFSQFRFAEEKEWDSEASCPKQNSAFYVD 179 
BIK   EEDLDPMEDFDSLECMEGSDALALRLACIGDEMDVSLRAPRLAQLSEVAMHSLGLAFIYD 95 
       :*::   : :* *. .*:* ::: *:. **.:.    * .    **.:  . . **  * 
AVEN  SELLVRALQELPLCLRLNVAAELVQGTVPLEVPQVKPKRTDDGKGLGMQLKGPLGPGGRG 239 
BIK   QTEDIR-----------DVLRSFMDGFTTLKENIMRFWRS-------------------- 124 
      .   :*           :*  .:::* ..*:   ::  *:                     
AVEN  PIFELKSVAAGCPVLLGKDNPSPGPSRDSQKPTSPLQSAGDHLEEELDLLLNLDAPIKEG 299 
BIK   --------------------PNPGS-----------WVSCEQVLLALLLLLALLLPLLSG 153 
                          *.**.             : :::   * *** *  *: .* 
AVEN  DNILPDQTSQDLKSKEDGEVVQEEEVCAKPSVTEEKNMEPEQPSTSKNVTEEELEDWLDS 359 
BIK   GLHLLLK----------------------------------------------------- 160 
      .  *  :                                                      
AVEN  MIS 362 
BIK   --- 
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putative BH3 motif in AVEN encompassing amino acids 
141-153 (FSVLLSSAGDSFS; Fig. 1). Although BH3-only 
proteins share homology mainly in the BH3 region [1,29], it 
is noteworthy that further sequence similarity can be found 
between AVEN and BIK [30] outside of the BH3 motif 
(58% similarity over a 77 amino acid region encompassing 
the putative BH3 motif (Fig. 2). The putative AVEN BH3 
motif contains two amino acids that are associated with 
BCL-xL specificity (FSVLLSSAGDSFS) according to 
binding studies carried out by Dutta and colleagues [11]. 
According to the PSSM model, AVEN would be predicted to 
bind BCL-xL with higher affinity than BCL2L14/BCLG 
[31] (see Supplemental File 2). 
 Chau and coworkers reported that AVEN binding to 
BCL-xL involved both the BH1 and BH4 domains of BCL-
xL [26]. The BH1 domain is part of the hydrophobic groove 
that binds BH3 motifs [32], suggesting a BH3-mediated 
interaction. N136 of BCL-xL forms a hydrogen bond with a 
carboxylate group of the conserved D in the BH3 motif [32]. 
Mutation of N136 to I eliminates this and leads to loss of a 
stabilizing interaction. One of the BCL-xL mutants that 
Chau and colleagues used that disrupted the BCL-xL-AVEN 
interaction (BCL-xL mutant 7) contained the N136I muta-
tion (V135A/N136I/W137L). Additionally, because AVEN 
bound to a deletion mutant of BCL-xL encompassing amino 
acids 26-83 but not to an N-terminally truncated mutant 
missing the first 61 amino acids, the N-terminal 25 amino 
acids of BCL-xL were implicated in the interaction. The N-
terminal 25 amino acids of BCL-xL comprise the BH4 
domain, suggesting a potential interdependency of the BCL-
xL-AVEN interaction interfaces similar to that described 
between BCL2 and BAX [33]. Consistent with the above 
speculation, the putative BH3 motif is conserved in Aven 
molecules across species (referred to as Region II in Fig. 1 of 
Ref. [34]). The exception to this is the Drosophila ortholog 
of Aven (dAven) that was recently identified by Zou and 
coworkers [34]. Interestingly, the Drosophila protein does 
not contain a recognizable BH3 motif: the conserved L and 
D residues as well as other amino acids are not preserved 
(e.g., an F at position 4a that AVEN shares with BIM and 
BAD and which makes a significant hydrophobic contribu-
tion to the BH3 domain interactions of these proteins; Supp-
lemental File 1) (Fig. 1). 
 Recent molecular dynamics simulations of pro-apoptotic 
BH3 peptide helices in aqueous medium have suggested a 
relationship between helix stability and their binding affini-
ties to BCL-xL. Lama and Sankararamakrishnan speculated 
that unlike the situation when the BH3 domains are part of a 
polypeptide chain and the hydrophobic residues insert 
themselves into the hydrophobic groove of an anti-apoptotic 
BCL2 family member, small peptides exposed to aqueous 
medium are likely to cluster among themselves to minimize 
contact with water molecules [5]. Therefore, the peptide 
simulations conducted represented an unfolding study and 
the authors were able to correlate the helical state of the BH3 
peptide at the end of the simulation with its experimental 
binding affinity for BCL-xL [4,5]. The stable helical seg-
ment that was found to be common to all the BH3 peptides is 
composed of a short five residue region with the conserved L 
located in the center, and they speculated that the conserved 
L could serve as a nucleation signal for an eventual longer 
helix upon binding to BCL-xL. We carried out molecular 
dynamics simulations of BCL-xL in complex with a 25-mer 
corresponding to the putative BH3 motif of AVEN and the 
corresponding region of dAven (highlighted in Fig. 1) [35]. 
As can be seen in Fig. 3, whereas the AVEN peptide 
exhibited significant internal helical stability at the end of 
the simulation period (Fig. 3A), there was almost a complete 
loss of helical character of the dAven peptide (Fig. 3B). 
Based on Lama and Sankararamakrishnan’s work [5,35], 
dAven would be predicted to have significantly reduced (if 
any) binding affinity for BCL-xL. Experimental data 
supports this prediction. In contrast to AVEN, no interaction 
was found between dAven and Drosophila BCL2 family 
members [34].  
 
Fig. (3). Results of molecular dynamics simulation of putative 
AVEN BH3 motif with BCL-xL. (A). Ribbon diagram of a peptide 
encompassing the putative BH3 motif of human AVEN 
(ESQRGTDFSVLLSSAGDSFSQFRFA; shown in red) complexed 
with BCL-xL. (B) Ribbon diagram of the corresponding peptide 
from Drosophila Aven (AQLRAGDFQQLAQFPSLGGGHFTFG; 
shown in red). See Fig. (1) and text for details. Simulations (20 ns) 
are based on an analogous 25-mer of the BAD BH3 motif and the 
BAD/BCL-xL structure (PDB code: 1G5J). 
 Collectively, these enticing correlations raise the strong 
possibility that the BH3 motif in AVEN is a functional BH3 
domain and that AVEN is a novel BH3-only protein. In 
addition to anti-apoptotic activity, AVEN also exhibits cell 
cycle regulatory function. After DNA damage, AVEN 
induces cell-cycle arrest via ataxia-telangiectasia-mutated 
(ATM) kinase activation [36]. A working hypothesis is that 
human AVEN (and most Aven orthologs) is a multifunc-
tional protein that modulates decisions of cell-cycle arrest 
and apoptosis during the DNA damage response, depending 
on the extent of damage [37]. In this regard, AVEN exhibits 
some striking functional similarities with RAD9A [38-40]; 
additional analogies can be drawn between AVEN and BID 
[41,42]. 
GRAMD4  
 Proteins containing GRAM (Glucosyltransferases, Rab-
like GTPase activators and Myotubularins) domains are 
predominately involved in membrane-associated processes 
[43]. GRAMD4 was originally identified as a downstream 
pro-apoptotic target of the transcription factor E2F1 (termed 
Death-Inducing-Protein), which localizes to mitochondria 
[44]. Upregulation of endogenous GRAMD4 by E2F1 
activation or GRAMD4 overexpression demonstrated greatly 
reduced cell viability in several in vitro systems accom-
panied by typical apoptotic features such as caspase-3 
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activation and cleavage of poly(ADP-ribose)-polymerase. 
Inhibition of endogenous protein function by small inter-
fering RNA rescued p53-negative cells from E2F1-induced 
apoptosis, indicating that GRAMD4 is an essential mediator 
of the p53-independent E2F1 death pathway.  
 Recent studies by the same group have provided evi-
dence that GRAMD4 is a p73 primary-response gene [45]. 
Pützer and colleagues showed that GRAMD4 is highly effi-
cient in inducing mitochondrial outer membrane permea-
bilization with release of the intermembrane space proteins 
cytochrome c and Smac/Diablo into the cytoplasm. Over-
expression of p73α and p73β isoforms, but not p53, led to 
direct GRAMD4 promoter transactivation. GRAMD4 was 
found to physically interact with BCL2, promoting BAX 
mitochondrial relocalization and oligomerization. In addi-
tion, GRAMD4 induced changes in BCL2 and BAX protein 
levels independent of transactivation effects at the level of 
the BCL2 or BAX promoters, suggesting that GRAMD4 is 
functioning through indirect perhaps post translational 
mechanisms, consistent with its apparent lack of a DNA 
binding and transactivation domain [44].  
 Our analysis identified a putative BH3 motif in 
GRAMD4 encompassing amino acids 218-230 (FVKNL 
SALSDWYS). It is noteworthy that, with the exception of 
BECN1, in all of the bona fide BH3-only genes reported to 
date, the BH3 domain is a structural and functional subunit 
encoded by a single short exon [29]. As shown in Table 1, 
the putative BH3 motif in GRAMD4 satisfies this condition. 
Although the authors did not detect a BH3 domain upon 
inspection of the protein, they reported that deletion of a 
region encompassing amino acids 92-176 disrupted the 
interaction of GRAMD4 with endogenous and ectopically 
expressed BCL2 protein. It remains to be demonstrated, but 
a possibility is that the 92-176 amino acid deletion in 
GRAMD4 led to a conformational change in the putative 
BH3 domain disrupting the interaction with the BH1-BH3 
hydrophobic groove interface of BCL2 [33,46]. 
HIP1R 
 HIP1R (Huntingtin interacting protein 1 related) is a 
multi-domain protein that regulates clathrin-mediated endo-
cytosis and actin assembly [47]. The related HIP1 protein 
was identified as an interactor of huntingtin, a protein that 
when mutated is involved in the genetic neurodegenerative 
disorder Huntington’s disease [48,49]. The mutated 
huntingtin has reduced affinity for HIP1, suggesting that the 
impaired interaction could be part of the disease mechanism 
[49]. HIP1R was identified on the basis of structural 
homology to HIP1 [50,51]. Both proteins have an N-
terminally localized ANTH (AP180 N-terminal homology) 
domain, a central coiled-coil domain, and a talin-like domain 
at the C-terminus. HIP1R binds inositol lipids via the ANTH 
domain [52] and actin via its talin like-domain [53]. In 
contrast to HIP1, HIP1R does not directly bind huntingtin 
[54]. 
 HIP1 was previously shown to have transforming func-
tion due to alterations in receptor trafficking [55]. Other 
work studying ANTH domains, suggested a mechanism by 
which the protein might facilitate cell survival by stabilizing 
receptor tyrosine kinases by binding 3-phosphorylated 
inositol lipids [56]. Hyun and coworkers provided evidence 
in support of such a mechanism for both HIP1 and HIP1R 
[52]. The authors speculated that HIP1 and HIP1R might 
Table 1. BH3 Motifs Encoded by a Single Exon 
 
                                            SDALALRLACIGDEMDVSLRAPRLAQLSEVAMHS BIK 
 
                                           VLGKAVHSLSRIGDELYLEPLEDG RAD9A 
 
                                          STMGQVGRQLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATS BAK1 
 
                                          ELEVECATQLRRFGDKLNFRQKLLNLISKLFCSGT PMAIP1/NOXA 
 
                                      DEEEQILAKIVELLKYSGDQLERK BCL2L14/BCL-G 
 
                                      KRGAKPVTNFVKNLSALSDWYSVYTSAIAFT GRAMD4 
 
                                     SEEEVVEGEKEVEALKKSADWVSDWSSRPENIPPK BNIP3L/NIX 
 
                                     GEPCSFDVAIIAGRLRMLGDQFNGELEASAKNVIAETIKGQ BCL2L15/BFK 
 
                                    DSESQEDIIRNIARHLAQVGDSMDRSIPPGLVNGLALQLRNTSRSEE BID 
 
                                 ADKSDPKPGVMTQEVGQLLQDMGDDVYQQYRSLTRQSSDFDTQSGFSIN HUWE1/MULE 
 
                               ASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARR BCL2L11/BIM 
 
                 GFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQR BAX 
 
               MCPCPLHRGRGPPAVCACSAGRLGLRSSAAQLTAARLKALGDELHQRTMWRRRARSRRAPAPGALPTYWPWLCAAAQVAALAAWLLGRRNL HRK 
 
            GNAGYRLPLPASFPAVLPIGEQPPEGQWQHQAEVQIARKLQCIADQFHRLHVQQ BMF 
 
  GPQPSLSLAEQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERR BBC3/PUMA 
 
GAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLWAAQRYGRELRRMSDEFVDSFK BAD 
 
With the exception of BECN1 (see Table 2), the BH3 motif in BH3-only BCL2 family proteins is encoded by a single short exon [29]. 
Known and putative BH3 motifs are in underlined bold blue type. 
Red highlighting indicates an amino acid encoded across a splice junction. 
Amino acid sequences are from the CCDS dataset (http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi). 
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bind to inositol lipid determinants of clathrin-coated vesicles, 
early endosomes, and recycling endosomes via their ANTH 
domains, causing the endocytic machinery to favor con-
tinued signaling either by stabilizing the early endosome or 
by stimulating growth factor receptor recycling to the cell 
surface. 
 Conflicting data exists as to whether overexpression of 
HIP1 has pro-apoptotic [57,58] or anti-apoptotic functions 
[59]. In particular, Rao and colleagues found that expression 
of an ANTH deletion mutant of HIP1, but not full-length 
HIP1, induced cell death in a dominant interfering manner 
[59]. The authors noted that two other reports of pro-
apoptotic activity used a different HIP1 cDNA which lacked 
the N-terminal sequence encoded by an upstream exon that 
had not been previously appreciated [60]. Thus, they sug-
gested that the reason for the discrepancy may be that cDNA 
used in the previous studies was functionally similar to the 
ANTH deletion mutant of HIP1 that they used. Following up 
on the HIP1 findings, Hyun and coworkers reported that a 
HIP1R mutant lacking the ANTH domain but not full-length 
HIP1R similarly induced apoptosis after ectopic expression 
in HEK293T cells [52].  
 Recently, HIP1R was identified in a screen for inter-
acting partners of BCL2L10 (human DIVA or BCL-B), a 
member of the BCL2 family that can either function as a 
pro- or anti-apoptotic protein [61]. Under the conditions 
employed in that study, ectopic expression of HIP1R 
induced apoptosis and augmented BCL2L10 association with 
caspase 9. In addition, a member of the proapoptotic BCL2 
family, BAK, was required for HIP1R to induce cell death, 
while BAX was dispensable. Deletion of both the N-terminal 
ANTH domain and the C-terminal talin-like domain of 
HIP1R greatly compromised its binding ability to BCL2L10. 
The C-terminal deletion (amino acids 816-1068) encom-
passed a putative BH3 motif (amino acids 882-894) that we 
identified (GATQLVEAADKVV; Table 2). 
 In addition to its well-accepted role as an antagonist of 
apoptosis, BCL2 has also been reported to function as a 
regulator of cell motility by interacting with and enhancing 
actin polymerization [62,63]. Besides binding to actin [47], it 
is evocative that HIP1R was identified in a proteomic screen 
for proteins that interact with dynein light chain LC8 
(although incorrectly listed as HIP1 in Table 2 of Ref. [64]). 
LC8 is a component of the dynein motor complexes that 
selectively sequester the the BIML and BIMEL isoforms of 
BIM and so regulate their cell death-inducing functions [65-
67]. In response to cellular damage that affects the cell 
cytoskeleton, BIM-LC8 complexes are released into the 
cytoplasm where they can interact with anti-apoptotic BCL2 
proteins, via their BH3 domains. These latter observations 
suggest further parallels between HIP1R and typical BH3-
only proteins. 
Putative BH3-Containing Proteins Associated with 
Apoptosis 
NME3 
 NME3 (non-metastatic cells 3) is a member of a family 
of 10 genes in humans named after the prototypic member 
NME1, which was identified as a suppressor of tumor 
metastasis (Nm23-H1) and exhibits nucleoside diphosphate 
kinase activity [68,69]. NME proteins are involved in a 
variety of physiological and pathological cellular processes 
including cell proliferation, differentiation, vesicular traffic-
king and adhesion as well as apoptosis [70]. Phylogenetic 
analysis of NME proteins shows two strongly supported 
distinct clusters, with NME3 belonging to same group as 
NME1, NME2 and NME4 [71].  
 NME3 was first identified as a gene associated with the 
blast crisis phase of chronic myeloid leukemia [72]. A cha-
racteristic feature of blast crisis is the differentiation arrest of 
the malignant hematopoietic progenitor cells. Constitutive 
expression of NME3 in a myeloid precursor cell line, which 
is growth-factor dependent for both proliferation and dif-
ferentiation, resulted in inhibition of differentiation. Notably, 
in the cell line model, differentiation arrest was associated 
with apoptotic cell death [72]. The mechanisms responsible 
for differentiation arrest and induction of apoptosis in this 
system are not known. A role for NME3 in the regulation of 
differentiation and apoptosis was also reported in neuroblas-
toma cells. However, in this situation overexpression of 
NME3 promoted differentiation while protecting the cells 
from apoptosis induced by serum deprivation [73]. The 
effects of NME3 expression thus seem to be dependent on 
cellular context. 
 We identified a putative BH3 motif in NME3 encom-
passing amino acids 129-141 (VGKNLIHGSDSVE; Table 
2). That NME3 might associate with BCL2 family members 
Table 2. BH3 Motifs Encoded by Two Exons 
 
                          RMMSTESANSFTLIGEASDGGTMENLSRRLKVTGDLFDIMSGQTDVDHPLCEECTDTLLDQLDTQLNVTENECQNYK BECN1 
 
                       GAATQQEFYAKNSRWTEGLISASKAVGWGATQLVEAADKVVLHTGKYEELIVCSHEIAASTAQLVAASK HIP1R 
 
                VWQGLDVVRTSRALIGATNPADAPPGTIRGDFCIEVGKNLIHGSDSVESARREIALWFRADELLCWEDSAGHWLYE NME3 
 
VEDDSDAETYGEENDEQGNYSKRKIVSNWDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDSEASCPKQ AVEN 
 
EMPDSAAALLGTCCKLQIIPTLCHLLRALSDDGVSDLEDPTLTPLKDTERFGIVQRLFASADISLERLKSSVKAVILKDSKVFPLLLCITLNGLCALGREHS DFNA5 
 
MEVLRRSSVFAAEIMDAFDRSPTDKELVAQAKALGREYVHARLLRAGLSWSAPERAAPVPGRLAEVCAVLLRLGDELEMIRPSVYRNVARQLHISLQSEPVVTDAFLAVAGHIFSAG 
 BOK 
 
Prior to the discovery of BECN1, BOK (a multidomain pro-apoptotic protein) was the only BCL2 family member in which the BH3 motif was found to be encoded by two exons 
[29]. 
Known and putative BH3 motifs are in underlined bold type. 
Blue highlighting indicates a different exon. 
Red highlighting indicates an amino acid encoded across a splice junction. 
Amino acid sequences are from the CCDS dataset (http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi). 
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is suggested from studies with the related human and rat 
NME2 proteins. NME2 was identified in a screen for 
proteins that interact with BCL2L10, a member of the BCL2 
family that can either function as a pro- or anti-apoptotic 
protein, described above [74]. BCL2L10 resides in the mem-
branes of intracellular organelles [75] and can translocate 
from endoplasmic reticulum to mitochondria upon apoptotic 
stimulus [76]. Kang and colleagues showed that ectopic 
expression of NME2 in HEK293T cells induced apoptosis 
where it colocalized with BCL2L10 in the cytoplasm. NME3 
has been reported to be localized within the cytoplasm and, 
at least partly, within mitochondria although no specific 
mitochondrial targeting sequence has been found [73,77]. 
NME2 contains a variant of the putative BH3 motif found in 
NME3 (VGRNIIHGSDSVE) encompassing amino acids 
112-124) which would satisfy a broader consensus definition 
but was not identified in our screen because of a conser-
vative substitution of the Φ2 hydrophobic L with isoleucine. 
DFNA5 
 The DFNA5 (deafness, autosomal dominant 5) gene was 
first identified as a gene whose expression is inversely corre-
lated with that of the estrogen receptor in breast carcinomas 
(accordingly, it was initially designated as ICERE-1 for 
inversely correlated with estrogen receptor expression) [78] 
and independently as a gene causing autosomal dominant 
hearing loss [79]. Epigenetic silencing of DFNA5 in several 
types of cancer, including a large percentage of gastric, 
colorectal and breast cancers, have implicated DFNA5 as a 
tumor suppressor gene [80-82].  
 In one study, decreased expression of DFNA5 in melano-
ma cell lines correlated with increased resistance to etopo-
side-induced apoptosis [83]. Subsequent work identified 
DFNA5 as a p53 target gene and its ectopic expression 
enhanced etoposide-induced cell death [84]. Intriguingly, in 
the same study, ectopic expression of DFNA5 in TP53-nega-
tive lung cancer cells inhibited etoposide-induced cell death. 
These contrasting results suggested that DFNA5 plays a role 
in the p53-regulated cellular response to genotoxic stress by 
somehow cooperating with p53, although the function of 
DFNA5 in this process remains to be elucidated. The 
DFNA5 gene has also be reported to be a glucocorticoid-
inducible gene in T cell acute lymphoblastic leukemia cells. 
Induction of DFNA5 mRNA correlates with glucocorticoid-
dependent apoptosis of the cells. In this case, however, its 
expression alone was not sufficient for apoptosis induction 
[85]. 
 A potential explanation for the differing results and 
insight into the mechanism of DFNA5-induced hearing loss 
was provided by identification of a fifth family with the dis-
order [86]. Comparative analyses of the five mutant DFNA5 
genes revealed different mutations but in each case the 
DFNA5 mRNA transcript was found to skip exon 8, result-
ing in a frameshift and a premature truncation of the protein. 
These findings suggested that DFNA5-associated hearing 
loss is attributable to a highly specific gain-of-function muta-
tion, in which skipping of one exon causes disease. Experi-
mental evidence congruent with this hypothesis was pre-
viously provided by the finding that transfection of mutant 
DFNA5 causes cell death [87]. Following up on these 
observations, de Beeck and coworkers recently demonstrated 
that DFNA5 is composed of two domains, separated by a 
hinge region. The first region (exon 2-exon 7) induces apop-
tosis when transfected in HEK293T cells, leading to the 
speculation that the second region may mask this domain 
and regulate its apoptosis inducing capability [88]. The 
DFNA5 exon 2-exon 7 construct was expressed mainly at 
the plasma membrane. In addition, it was observed in the 
cytoplasm in a granulated manner. The putative BH3 motif 
in DFNA5 is formed across the splice junction of exons 9 
and 10 (LCHLLRALSDDGV; Table 2). Therefore, a poten-
tial scenario is that the BH3-like domain encoded by exons 9 
and 10 of DFNA5 facilitates association of the protein with 
BCL2 family members. Mutations causing hearing loss or 
experimental truncation of the protein disrupt these interac-
tions, releasing the amino terminal portion of the protein to 
initiate apoptosis by as yet unknown mechanisms. The vary-
ing effects of wild-type DFNA5 observed in the different 
cancer apoptosis studies may relate to levels of the protein 
expressed, and indicate a requirement for p53. 
CONCLUSIONS 
 We have identified a number of potential BH3-only 
proteins which can now be evaluated by direct experiment-
ation for BH3 domain-mediated interactions with BCL2 
family members and regulation of cell death mechanisms. In 
addition to the candidates highlighted in the text, the list 
provided as Supplemental File 2 should prove to be a useful 
resource for further data mining of novel BH3-containing 
proteins. It is important to note, however, that this list is by 
no means a comprehensive compilation of all potential BH3-
only proteins in the human proteome. For example, the pro-
apoptotic proteins BNIP1 and BNIP3 [89], which contain 
diverged BH3 motifs (Supplemental File 1), were not identi-
fied by this screen; nor were several other purported novel 
BH3-only proteins with atypical BH3-like sequences: such 
as MOAP1/MAP-1 (modulator of apoptosis) [90], SPIKE 
(small protein with inherent killing effect) [91], BLID/ 
BRCC2 (BH3-like motif containing, cell death inducer) [92], 
TGM2 (tissue transglutaminase) [93], APOL6 (apolipopro-
tein L6) [94], APOL1 (apolipoprotein L1) [95] or HEBP2/ 
SOUL [96]. Clearly, further relaxation in the stringency of 
the BH3 motif definition, and refinement of PSSM models 
and molecular dynamics simulations will be necessary to 
extend this strategy in order for it to become all inclusive.  
 We were struck by the fact that besides apoptosis the list 
of potential BH3-only candidates identified by the 13-amino 
acid BH3 consensus sequence that we employed is enriched 
for proteins associated with autophagy (beyond BECN1) as 
well as a broad spectrum of cellular stress responses such as 
endoplasmic reticulum stress, oxidative stress, antiviral 
defense and the DNA damage response (Supplemental File 
2). It seems possible that some of the BH3-like sequences, if 
not bona fide BH3 domains belonging to novel BCL2 family 
members, represent core modules that participate in protein-
protein interactions transmitting various stress signals to 
mitochondria and the nucleus, facilitating crosstalk between 
apoptotic pathways and those involved in autophagy and cell 
cycle checkpoint control [97-99]. In accord with this 
conjecture, during the writing of this manuscript Kimchi and 
colleagues published the results of a study in which they 
identified the autophagy protein ATG12 as a novel BH3-
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only proapoptotic protein that binds to BCL2 and MCL-1 
[100]. ATG12 is not present in our list of candidates because 
its atypical BH3-like region deviates from our consensus 
motif at two positions. However, one of the other autophagy 
genes that they identified as a positive regulator of apoptosis 
but did not characterize, ATG16L1, is present (Supplemental 
File 2, page 48) (Fig. 4). 
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